JP2019520801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520801A5 JP2019520801A5 JP2018558668A JP2018558668A JP2019520801A5 JP 2019520801 A5 JP2019520801 A5 JP 2019520801A5 JP 2018558668 A JP2018558668 A JP 2018558668A JP 2018558668 A JP2018558668 A JP 2018558668A JP 2019520801 A5 JP2019520801 A5 JP 2019520801A5
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- dagk
- strain
- bacterial strain
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 50
- 235000014655 lactic acid Nutrition 0.000 claims 25
- 239000004310 lactic acid Substances 0.000 claims 25
- 108010062677 Diacylglycerol Kinase Proteins 0.000 claims 19
- 102000011107 Diacylglycerol Kinase Human genes 0.000 claims 19
- 230000001580 bacterial effect Effects 0.000 claims 14
- 150000001982 diacylglycerols Chemical class 0.000 claims 10
- 241000186604 Lactobacillus reuteri Species 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 7
- 241000894006 Bacteria Species 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 6
- 230000007815 allergy Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 5
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 235000020932 food allergy Nutrition 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 4
- 230000003266 anti-allergic effect Effects 0.000 claims 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 206010016946 Food allergy Diseases 0.000 claims 2
- 206010048908 Seasonal allergy Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000000172 cytosol Anatomy 0.000 claims 2
- 101150030459 dagK gene Proteins 0.000 claims 2
- 201000004338 pollen allergy Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- 241001070017 Lactobacillus fermentum ATCC 14931 Species 0.000 claims 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 1
- 208000008267 Peanut Hypersensitivity Diseases 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 229960001271 desloratadine Drugs 0.000 claims 1
- 229960001971 ebastine Drugs 0.000 claims 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003592 fexofenadine Drugs 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000010853 peanut allergy Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650620 | 2016-05-09 | ||
| SE1650620-6 | 2016-05-09 | ||
| PCT/SE2017/050455 WO2017196235A1 (en) | 2016-05-09 | 2017-05-08 | Selection of bacterial strains useful in allergy treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520801A JP2019520801A (ja) | 2019-07-25 |
| JP2019520801A5 true JP2019520801A5 (enExample) | 2020-06-18 |
| JP7030716B2 JP7030716B2 (ja) | 2022-03-07 |
Family
ID=58873850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558668A Active JP7030716B2 (ja) | 2016-05-09 | 2017-05-08 | アレルギー治療に有用な細菌株の選択 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11135255B2 (enExample) |
| EP (1) | EP3454874A1 (enExample) |
| JP (1) | JP7030716B2 (enExample) |
| CN (1) | CN109195612A (enExample) |
| AU (1) | AU2017262408A1 (enExample) |
| BR (1) | BR112018072511A2 (enExample) |
| CA (1) | CA3023867A1 (enExample) |
| CL (1) | CL2018003167A1 (enExample) |
| MX (1) | MX392754B (enExample) |
| SG (1) | SG11201809551TA (enExample) |
| WO (1) | WO2017196235A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4081229A1 (en) * | 2019-12-24 | 2022-11-02 | Iowa State University Research Foundation, Inc. | Control of histamine to promote health and control enterocolitis using probiotic compositions and/or histamine degrading enzymes |
| JP7515153B2 (ja) * | 2020-03-06 | 2024-07-12 | 学校法人麻布獣医学園 | 乳酸菌含有組成物 |
| CN113073066B (zh) * | 2021-04-16 | 2022-01-04 | 段云峰 | 罗伊氏乳杆菌及其应用、组合物、药物和食品 |
| CN114317326B (zh) * | 2021-12-06 | 2023-09-12 | 浙江工商大学 | 一种用于缓解过敏反应的清酒乳杆菌及制备方法 |
| CN115025130A (zh) * | 2022-06-02 | 2022-09-09 | 广东南芯医疗科技有限公司 | 罗伊氏乳杆菌e9在制备治疗或预防过敏性疾病药物中的应用 |
| CN116376758B (zh) * | 2023-03-15 | 2024-07-02 | 广东南芯医疗科技有限公司 | 詹氏乳杆菌ls06及其在制备治疗或预防过敏性疾病药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK154078C (da) * | 1981-02-06 | 1989-05-22 | Ucb Sa | Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf |
| JP4212838B2 (ja) * | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
| AU2002951270A0 (en) * | 2002-09-06 | 2002-09-19 | Vri Biomedical Ltd | Probiotic Bacterium and Methods of Use |
| KR100507417B1 (ko) * | 2003-01-27 | 2005-08-10 | (주) 피엘바이오 | 알레르기 질환 예방 및 치료 기능을 가진 유산균과 이를 함유한 항알레르기 제품 |
| AU2005303893A1 (en) | 2004-11-11 | 2006-05-18 | Argenta Discovery Ltd | Pyrimidine compounds as histamine modulators |
| EP2674493B1 (en) * | 2006-04-13 | 2017-12-27 | Arrowhead Research Corporation | RNAi-mediated inhibition of histamine receptor H1-related conditions |
| JP2008127365A (ja) | 2006-11-24 | 2008-06-05 | Kowa Co | アレルギー性疾患の予防及び／又は治療剤 |
| US20110217290A1 (en) * | 2008-08-18 | 2011-09-08 | Manel Jordana | Treatment and/or prevention of peanut induced anaphylaxis |
| JP2011254773A (ja) | 2010-06-11 | 2011-12-22 | Bio Plan:Kk | 乳酸菌の菌株及びこれを利用したアレルギー抑制剤 |
| WO2012012390A1 (en) * | 2010-07-19 | 2012-01-26 | Marvphyt Development Llc | Botanical composition and methods of manufacture and use |
| US20130022586A1 (en) | 2011-07-21 | 2013-01-24 | James Versalovic | Production and use of bacterial histamine |
| WO2014130759A1 (en) * | 2013-02-21 | 2014-08-28 | University Of Rochester | Methods of using histamine receptor agonists and antagonists |
| JP6195268B2 (ja) | 2013-07-18 | 2017-09-13 | 国立大学法人徳島大学 | 鼻炎の予防治療装置 |
| SG11201705479UA (en) * | 2015-03-26 | 2017-10-30 | Biogaia Ab | Histamine-producing bacterial strains and their use in cancer |
-
2017
- 2017-05-08 BR BR112018072511A patent/BR112018072511A2/pt not_active Application Discontinuation
- 2017-05-08 JP JP2018558668A patent/JP7030716B2/ja active Active
- 2017-05-08 SG SG11201809551TA patent/SG11201809551TA/en unknown
- 2017-05-08 WO PCT/SE2017/050455 patent/WO2017196235A1/en not_active Ceased
- 2017-05-08 MX MX2018013660A patent/MX392754B/es unknown
- 2017-05-08 US US16/099,258 patent/US11135255B2/en active Active
- 2017-05-08 EP EP17727008.9A patent/EP3454874A1/en not_active Ceased
- 2017-05-08 CA CA3023867A patent/CA3023867A1/en active Pending
- 2017-05-08 AU AU2017262408A patent/AU2017262408A1/en not_active Abandoned
- 2017-05-08 CN CN201780028567.1A patent/CN109195612A/zh active Pending
-
2018
- 2018-11-08 CL CL2018003167A patent/CL2018003167A1/es unknown
-
2021
- 2021-08-31 US US17/462,227 patent/US12201656B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520801A5 (enExample) | ||
| Bourrie et al. | The microbiota and health promoting characteristics of the fermented beverage kefir | |
| Martens et al. | Probiotics for the airways: potential to improve epithelial and immune homeostasis | |
| Ou et al. | Heat‐killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization | |
| Sharma et al. | Antibiotic resistance among commercially available probiotics | |
| Rather et al. | Probiotics and atopic dermatitis: an overview | |
| Wu et al. | Inhibitory effect of Lactobacillus salivarius on Streptococcus mutans biofilm formation | |
| Mishra et al. | A brief overview on probiotics: the health friendly microbes | |
| Jonganurakkun et al. | Pediococcus pentosaceus NB-17 for probiotic use | |
| RU2018113245A (ru) | Новая лактобактерия, характеризующаяся различными функциями, и ее применение | |
| Ng et al. | Evaluation of probiotic potential of lactic acid bacteria isolated from traditional Malaysian fermented Bambangan (Mangifera pajang) | |
| JP2015213501A5 (enExample) | ||
| RU2014107770A (ru) | Композиция, содержащая n-ацетилцистеин и/или микроинкапсулированный защищенный от действия желудочного сока лизоцим в сочетании с пробиотическими бактериями, способная восстанавливать собственный барьерный эффект желудка, который утрачивается во время фармалогического лечения желудочной гиперацидности | |
| Helmy et al. | In vitro evaluation of the impact of the probiotic E. coli Nissle 1917 on Campylobacter jejuni’s invasion and intracellular survival in human colonic cells | |
| Kitazawa et al. | Probiotics: immunobiotics and immunogenics | |
| GB2460781A (en) | Probiotic bifidobacterium strains | |
| MX356598B (es) | Bifidobacterium longum. | |
| Prajapati et al. | Advances in probiotics research: mechanisms of action, health benefits, and limitations in applications | |
| Scully et al. | Bifidobacterium infantis suppression of Peyer’s patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+ CD25+ T cell numbers | |
| MX383749B (es) | Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas | |
| HK1198326A1 (zh) | 用於预防或治疗上呼吸道感染的鼠李糖乳杆菌和动物双歧杆菌乳亚种 | |
| US11969445B2 (en) | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH | |
| Chiu et al. | Characterisation of bifidobacteria with immunomodulatory properties isolated from human breast milk | |
| Qian et al. | Supplementation of triple viable probiotics combined with dietary intervention is associated with gut microbial improvement in humans on a high‑fat diet | |
| JP2006273852A5 (enExample) |